BR0100790A - Oxamidas como inibidores de impdh - Google Patents
Oxamidas como inibidores de impdhInfo
- Publication number
- BR0100790A BR0100790A BR0100790-4A BR0100790A BR0100790A BR 0100790 A BR0100790 A BR 0100790A BR 0100790 A BR0100790 A BR 0100790A BR 0100790 A BR0100790 A BR 0100790A
- Authority
- BR
- Brazil
- Prior art keywords
- represents hydrogen
- lower alkyl
- diseases
- agent
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Patente de Invenção: <B>"OXAMIDAS COMO INIBIDORES DE IMPDH"<D>. São descritos os compostos da fórmula geral onde R¹ representa heterociclila; R² representa hidrogênio, alquila inferior não substituída, alcóxi inferior, halo, hidróxi ou ciano; R³ representa hidrogênio, alquila inferior não-substituída, alcóxi inferior, halo ou ciano; R^ 4^ representa hidrogênio, alquila inferior, cicloalquila inferior, arila ou heterociclila; R^ 5^ representa hidrogênio, alquila inferior não-substituída, alcóxi inferior, halo ou ciano; R^ 6^ representa hidrogênio, alquila inferior não-substituída, alcóxi inferior, halo ou ciano; R^ 7^ representa hidrogênio ou alquila inferior não-substituída; R^ 8^ representa hidrogênio ou alquila inferior não-substituída; ou R^ 4^ e R^ 8^ juntos com o átomo de nitrogênio ao qual eles estão ligados representam heterociclila; e seus sais farmaceuticamente aceitáveis. Os derivados de oxamida descritos são inibidores da desidrogenase do monofosfato de enzima inosina (IMPDH). Eles podem ser usados como medicamento, especialmente para o tratamento de condições ou doenças imunes mediadas, doenças virais, doenças bacterianas, doenças parasíticas, inflamação, doenças inflamatórias, doenças vasculares hiperproliferativas, tumores ou câncer. Eles podem ser usados sozinhos ou em combinação com outros agentes terapeuticamente ativos, por exemplo, um imunossupressor, um agente quimioterapêutico, um agente antiviral, um antibiótico, um agente antiparasítico, um agente antiinflamatório, um agente antifúngico e/ou um agente de hiperproliferação antivascular.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0004392A GB0004392D0 (en) | 2000-02-24 | 2000-02-24 | Oxamide derivatives |
GB0015877A GB0015877D0 (en) | 2000-06-28 | 2000-06-28 | Oxamide derivatives |
GB0020322A GB0020322D0 (en) | 2000-08-17 | 2000-08-17 | Oxamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0100790A true BR0100790A (pt) | 2001-09-25 |
Family
ID=27255557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0100790-4A BR0100790A (pt) | 2000-02-24 | 2001-02-23 | Oxamidas como inibidores de impdh |
Country Status (8)
Country | Link |
---|---|
US (1) | US6867299B2 (pt) |
EP (1) | EP1127883A3 (pt) |
JP (1) | JP2001261663A (pt) |
KR (1) | KR20010085490A (pt) |
CN (1) | CN1310179A (pt) |
AR (1) | AR027464A1 (pt) |
BR (1) | BR0100790A (pt) |
CA (1) | CA2337588A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1127054A4 (en) | 1998-10-29 | 2006-11-02 | Bristol Myers Squibb Co | INHIBITORS OF IMPDH ENZYME |
WO2004058728A1 (ja) * | 2002-12-24 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | 新規なエチレンジアミン誘導体 |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
JP2006521304A (ja) * | 2003-03-24 | 2006-09-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | rafキナーゼ阻害剤として有用なオキサミド誘導体 |
MXPA05007609A (es) * | 2003-04-23 | 2005-09-30 | Japan Tobacco Inc | Antagonista de un receptor sensible al calcio. |
GB0326393D0 (en) * | 2003-11-12 | 2003-12-17 | Ares Trading Sa | Cytokine antagonist molecules |
AU2005240784C1 (en) | 2004-05-07 | 2011-12-22 | Janssen Pharmaceutica N.V. | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
UA87328C2 (en) * | 2004-08-30 | 2009-07-10 | Янссен Фармацевтика Н.В. | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
ES2334246T3 (es) | 2004-08-30 | 2010-03-08 | Janssen Pharmaceutica Nv | Derivados triciclos de adamantilamida como inhibidores de la 11-beta-hidroxiesteroide-deshidrogenasa. |
WO2007143557A2 (en) * | 2006-06-02 | 2007-12-13 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal parasitic infections |
CA2700028A1 (en) * | 2007-09-21 | 2009-04-02 | Sanofi-Aventis | (carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament |
EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
US9776963B2 (en) * | 2008-11-10 | 2017-10-03 | The Trustees Of The University Of Pennsylvania | Small molecule CD4 mimetics and uses thereof |
WO2010108187A2 (en) | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
WO2012020484A1 (ja) * | 2010-08-11 | 2012-02-16 | アグロカネショウ株式会社 | 3-アミノオキサリルアミノベンズアニリド誘導体及びこれを有効成分とする殺虫、殺ダニ剤 |
WO2012020483A1 (ja) * | 2010-08-11 | 2012-02-16 | アグロカネショウ株式会社 | 3-アミノオキサリルアミノベンズアミド誘導体及びこれを有効成分とする殺虫、殺ダニ剤 |
CA2845933C (en) | 2011-09-06 | 2020-06-09 | New York Blood Center, Inc. | Hiv inhibitors |
US8916702B2 (en) * | 2012-02-06 | 2014-12-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
BR112014030720A8 (pt) | 2012-06-08 | 2021-06-22 | The Us Gov As Represented By The Department Of Veterans Affairs | composto, composição farmacêutica e usos de inibidores de fbx03 |
CN105008323B (zh) * | 2012-10-31 | 2018-11-06 | 密歇根大学董事会 | 纤溶酶原激活物抑制因子-1抑制剂和其使用方法 |
WO2015089087A1 (en) | 2013-12-09 | 2015-06-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and methods for treating respiratory injury or disease |
WO2016025681A1 (en) | 2014-08-13 | 2016-02-18 | The Trustees Of The University Of Pennsylvania | Inhibitors of hiv-1 entry and methods of use thereof |
US10266526B2 (en) * | 2014-09-10 | 2019-04-23 | Epizyme, Inc. | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer |
ES2764440T3 (es) | 2014-09-19 | 2020-06-03 | New York Blood Center Inc | Fenilpirrolcarboxamidas sustituidas con actividad terapéutica en VIH |
WO2016094659A1 (en) | 2014-12-10 | 2016-06-16 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and methods for treating diseases and conditions |
EP3657946A4 (en) | 2017-07-27 | 2021-04-07 | The Regents of The University of Michigan | PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITOR AND METHOD OF APPLICATION |
AU2019242628A1 (en) | 2018-03-26 | 2020-09-24 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
CN109503528B (zh) * | 2018-05-15 | 2022-06-14 | 天津国际生物医药联合研究院 | 一种化合物及其在抗沙粒病毒感染中的应用 |
EP3946294A4 (en) * | 2019-03-26 | 2022-12-28 | University of Cincinnati | METHOD FOR MANUFACTURING A TIMED RELEASE PRODRUG |
CN109824583B (zh) * | 2019-03-27 | 2022-04-08 | 山东大学 | 一种苯基草酰胺类hiv-1抑制剂及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2463774A1 (fr) | 1979-08-21 | 1981-02-27 | Yamanouchi Pharma Co Ltd | Derives du 2-phenylimidazo(2,1-b)benzothiazole |
GB8310435D0 (en) | 1983-04-18 | 1983-05-25 | Fujisawa Pharmaceutical Co | Triazine derivatives |
US5362481A (en) | 1993-03-05 | 1994-11-08 | 3V Inc. | Benzofuran derivatives and the use thereof as stabilizers against UV radiations |
DK0871619T3 (da) | 1995-12-29 | 2003-03-03 | Boehringer Ingelheim Pharma | Phenylthiazolderivater med antiherpesvirusegenskaber |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
EP0902782A1 (en) | 1996-04-23 | 1999-03-24 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
US5932600A (en) | 1997-03-14 | 1999-08-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
ES2232946T3 (es) | 1997-04-30 | 2005-06-01 | Eli Lilly And Company | Agentes antitromboticos. |
KR20010041811A (ko) | 1998-03-12 | 2001-05-25 | 온토젠 코포레이션 | 단백질 티로신 포스파타제의 조절제 |
AU2713699A (en) | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
JP2002512997A (ja) | 1998-04-29 | 2002-05-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh酵素のインヒビター |
US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
EP1127054A4 (en) * | 1998-10-29 | 2006-11-02 | Bristol Myers Squibb Co | INHIBITORS OF IMPDH ENZYME |
-
2001
- 2001-02-08 US US09/779,116 patent/US6867299B2/en not_active Expired - Fee Related
- 2001-02-16 EP EP01103521A patent/EP1127883A3/en not_active Withdrawn
- 2001-02-20 CA CA002337588A patent/CA2337588A1/en not_active Abandoned
- 2001-02-21 AR ARP010100764A patent/AR027464A1/es unknown
- 2001-02-23 KR KR1020010009107A patent/KR20010085490A/ko not_active Application Discontinuation
- 2001-02-23 BR BR0100790-4A patent/BR0100790A/pt not_active Application Discontinuation
- 2001-02-23 CN CN01104906A patent/CN1310179A/zh active Pending
- 2001-02-26 JP JP2001051064A patent/JP2001261663A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1310179A (zh) | 2001-08-29 |
US6867299B2 (en) | 2005-03-15 |
EP1127883A3 (en) | 2002-08-07 |
EP1127883A2 (en) | 2001-08-29 |
US20020052513A1 (en) | 2002-05-02 |
KR20010085490A (ko) | 2001-09-07 |
AR027464A1 (es) | 2003-03-26 |
JP2001261663A (ja) | 2001-09-26 |
CA2337588A1 (en) | 2001-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0100790A (pt) | Oxamidas como inibidores de impdh | |
IL127965A0 (en) | Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same | |
SK114894A3 (en) | Set for treatment of tumors of mammalia | |
PT879820E (pt) | Analogos de benzamida, uteis como inibidores de enzima de reparacao de adn (adp-ribosil-transferase, adprt) | |
BR0205890A (pt) | Pirazolopirimidinas como agentes terapêuticos | |
NO20021401L (no) | Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser | |
BR0010746A (pt) | Derivados heterocìclicos úteis com agentes anticâncer | |
EP0310122B1 (en) | Antifungal composition | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
IL100612A0 (en) | Cyclic ketal derivatives,their preparation and pharmaceutical compositions containing them | |
WO2000064874A3 (en) | Heterosubstituted pyridine derivatives as pde 4 inhibitors | |
DK0780125T3 (da) | Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler | |
Then et al. | New analogs of trimethoprim | |
ATE219085T1 (de) | 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren | |
IT1214618B (it) | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. | |
DK1209166T3 (da) | Hidtil ukendte A-500 359-derivater | |
EP0579646B1 (en) | Anti-cancer antracene derivatives | |
PT1248776E (pt) | Taxanos semi-sinteticos com actividades antitumor e anti-angiogeneticas | |
ID23783A (id) | Anti fungi 2.4.4.-trisubstitusi-1,3-dioksolan | |
DE69910738D1 (de) | Fungizide zusammensetzung enthaltend ein n-benzoyl-n'-phenyl-harnstoff derivat | |
MA26755A1 (fr) | Nouveaux derives oxamides, leur fabrication et les preparations pharmaceutiques les contenant. | |
BR0208716A (pt) | Derivativos de quinolina e seu uso como antibióticos | |
US3260732A (en) | N-(methylcarbamyl)-5-nitro-2-furamidoxime | |
JP2001081029A (ja) | テロメラーゼ阻害剤 | |
TH13242EX (th) | สารประกอบใหม่ชื่อว่า "เลอุสโทรดัคซิน" การเตรียมและประโยชน์ในการใช้รักษาของสารประกอบเหล่านี้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |